PDL/Roche Targeting Broad Zenapax Asthma Indication Under Development Deal
This article was originally published in The Pink Sheet Daily
Executive Summary
Roche signs on to PDL’s plans for daclizumab in development/marketing agreement for “asthma and related respiratory diseases.” PDL hopes initial asthma indication will be broader than that of Genentech/Novartis’ Xolair.